Dimethyl Sulfoxide-Induced Toxicity in Cord Blood Stem Cell Transplantation: Report of Three Cases and Review of the Literature

Ruíz-Delgado, Guillermo J.; Mancı́as-Guerra, Consuelo; Tamez-Gómez, Edna L.; Rodríguez-Romo, Laura; López-Otero, Avril; Hernández-Arizpe, Ana; Gómez‐Almaguer, David; Ruíz‐Argüelles, Guillermo J.

doi:10.1159/000227267

Cited by 73 publications

(43 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The liposomes displayed efficient cellular uptake and anticancer efficacy in prostate cancer cells, comparable to that of the free drug reconstituted in DMSO. The advantage of encapsulating celastrol in liposomes is the elimination of the need for solubilizing agents, such as DMSO, which exhibit non-specific toxicity that has hindered their clinical use (Ruiz-Delgado et al, 2009, Rubin, 1975, Swanson, 1985, Montaguti et al, 1994, Vogin et al, 1970). Furthermore, celastrol and other small molecule drugs have short blood circulation times, due to rapid excretion by the kidneys.…”

Section: Resultsmentioning

confidence: 99%

Evaluation of anticancer activity of celastrol liposomes in prostate cancer cells

Wolfram

Suri

Huang

et al. 2014

Journal of Microencapsulation

View full text Add to dashboard Cite

Context Celastrol, a natural compound derived from the herb Tripterygium wilfordii, is known to have anticancer activity, but is not soluble in water. Objective Formation of celastrol liposomes, to avoid the use of toxic solubilizing agents. Materials and methods Two different formulations of pegylated celastrol liposomes were fabricated. Liposomal characteristics and serum stability were determined using dynamic light scattering. Drug entrapment efficacy and drug release were measured spectrophotometrically. Cellular internalization and anticancer activity was measured in prostate cancer cells. Results Liposomal celastrol displayed efficient serum stability, cellular internalization and anticancer activity, comparable to that of the free drug reconstituted in dimethyl sulfoxide. Discussion and conclusion Liposomal celastrol can decrease the viability of prostate cancer cells, while eliminating the need for toxic solubilizing agents.

show abstract

Section: Resultsmentioning

confidence: 99%

Evaluation of anticancer activity of celastrol liposomes in prostate cancer cells

Wolfram

Suri

Huang

et al. 2014

Journal of Microencapsulation

View full text Add to dashboard Cite

show abstract

“…For instance, dimethyl sulfoxide (DMSO) is usually the first agent of choice for cell culture [34, 35]. However, DMSO has displayed toxicity in multiple studies [36–39]. Moreover, several clinically approved hydrophobic drugs are formulated with toxic agents.…”

Section: Reduction Of Drug Toxicity Through Nanomedicinementioning

confidence: 99%

Safety of Nanoparticles in Medicine

Wolfram¹,

Zhu

Yang

et al. 2015

CDT

441

246

View full text Add to dashboard Cite

Nanomedicine involves the use of nanoparticles for therapeutic and diagnostic purposes. During the past two decades, a growing number of nanomedicines have received regulatory approval and many more show promise for future clinical translation. In this context, it is important to evaluate the safety of nanoparticles in order to achieve biocompatibility and desired activity. However, it is unwarranted to make generalized statements regarding the safety of nanoparticles, since the field of nanomedicine comprises a multitude of different manufactured nanoparticles made from various materials. Indeed, several nanotherapeutics that are currently approved, such as Doxil and Abraxane, exhibit fewer side effects than their small molecule counterparts, while other nanoparticles (e.g. metallic and carbon-based particles) tend to display toxicity. However, the hazardous nature of certain nanomedicines could be exploited for the ablation of diseased tissue, if selective targeting can be achieved. This review discusses the mechanisms for molecular, cellular, organ, and immune system toxicity, which can be observed with a subset of nanoparticles. Strategies for improving the safety of nanoparticles by surface modification and pretreatment with immunomodulators are also discussed. Additionally, important considerations for nanoparticle safety assessment are reviewed. In regards to clinical application, stricter regulations for the approval of nanomedicines might not be required. Rather, safety evaluation assays should be adjusted to be more appropriate for engineered nanoparticles.

show abstract

“…As the clinical symptoms appeared during or soon after the Schlegel et al 2009), so bringing the total to 27 case studies. Many of these indicated the observed reactions were tenuously or convincingly associated with the DMSO (Corso et al 1993;Zenhausern et al 2000;Hoyt et al 2000;Benekli et al 2000;Windrum and Morris 2003;Bauwens et al 2005;Chen-Plotkin et al 2007;Mueller et al 2007;Junior et al 2008;Otrock et al 2008;Abdelkefi et al 2009;Ruiz-Delgado et al 2009) or the presence of lysed cells (Ruiz-Delgado et al 2009). Whilst others implicated hypothermia of the infusate (Hequet et al 2002), anaphylaxis due to DMSO (Rapoport et al 1991), the rate of infusion (Junior et al 2008) or the volume of cryopreserved stem cells (Dhodapkar et al 1994).…”

Section: Adverse Reactions In Recipientsmentioning

confidence: 99%

Historical perspectives and the future of adverse reactions associated with haemopoietic stem cells cryopreserved with dimethyl sulfoxide

2011

View full text Add to dashboard Cite

A retrospective review of the published literature identified several hundred adverse reactions (e.g. nausea, chills, cardiac arrhythmias, neurological symptoms and respiratory arrest) associated with the transplantation of stem cells cryopreserved with dimethyl sulfoxide. The occurrences of these are generally accepted as commonplace, as the majority of reactions are transient, whilst a few patients may require clinical treatment. This exploratory study is a collation of the historical data and the expectations for the notification of serious adverse reactions. Outline information is presented on the development of related European Directives, some technical aspects of dimethyl sulfoxide and the sequential stages of preservation and administration.

show abstract

Dimethyl Sulfoxide-Induced Toxicity in Cord Blood Stem Cell Transplantation: Report of Three Cases and Review of the Literature

Cited by 73 publications

References 63 publications

Evaluation of anticancer activity of celastrol liposomes in prostate cancer cells

Evaluation of anticancer activity of celastrol liposomes in prostate cancer cells

Safety of Nanoparticles in Medicine

Historical perspectives and the future of adverse reactions associated with haemopoietic stem cells cryopreserved with dimethyl sulfoxide

Contact Info

Product

Resources

About